Download PDF
Thromb Haemost 1990; 63(03): 392-402
DOI: 10.1055/s-0038-1645054
Original Articles
Schattauer GmbH Stuttgart

Development of a Heat-Treated Factor VIII/ von Willebrand Factor Concentrate Prepared from Heparinized Plasma

D S Palmer
The Ottawa Centre of the Canadian Red Cross, Blood Transfusion Service, ottawa,Ontario,Canada
,
P R Ganz
+   Departments of Biochemistry and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada
,
H Perkins
The Ottawa Centre of the Canadian Red Cross, Blood Transfusion Service, ottawa,Ontario,Canada
,
D Rosborough
The Ottawa Centre of the Canadian Red Cross, Blood Transfusion Service, ottawa,Ontario,Canada
,
G Rock
*   Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 11 November 1988

Accepted after revision 07 March 1990

Publication Date:
24 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A high yield, intermediate purity factor VIII concentrate derived from heparinized plasma has been developed which can be heat-treated at 60 °C, 68 °C or 80 °C/72 h to permit inactivation of viral contaminants which may be present. After cold reprecipitation of the heparinized cryoprecipitate (CRC), the resolubilized CRC precipitate was adjusted to 25-30 mg/ml protein and pH 6.35 ± 0.1 and incubated for 1 h at 8 °C. After centrifugation to remove the precipitated fibrinogen and fibronectin, a factor VIII-rich supernatant can be recovered which contains > 500 units of VIII : C per liter of starting plasma (Method I product) at a purity of 1.5 U/mg protein. Adjusted to 50 mM glycine and pH 6.8, the product can be lyophilized and heat-treated at 60 °C/72 h without a significant loss of VIII :C activity. However, at 68 °C or 80 °C/72 h, temperatures now reported to be more effective in viral inactivation, the recoveries were reduced to 68 and 33% respectively. Significantly improved recoveries after heat-treatment (HT) at 68 °C or 80 °C/72 h were achieved if the 8 °C supernatant product was prepared by a modified procedure (Method II). This further reduces the fibrinogen content of the product while maintaining VIII : C yields > 500 U/l at a purity of 1.9 U/mg. When adjusted to 50 mM glycine and 1-2% (w/v) sucrose (pH 6.8), lyophilized and heat treated at 60 °C, 68 °C or 80 °C/72 h, the VIII :C recoveries of Method II product were 88-100%, 79-84% and 80-83% of pre-HT levels respectively. The yield of VIII : C was > 400 U/l at a purity of 1.6-1.4 U/mg at 1-2% (w/v) sucrose even after the severe heat-treatment at 80 °C. In addition, the von Willebrand factor multimers are similar in size and triplet pattern to those observed in routine cryoprecipitate preparations.

 

  • References

  • 1 Rock GA, Cruickshank WH, Tackaberry ES, Palmer DS. Improved yields of factor VIII from heparinized plasma. Vox Sang 1979; 36: 294-300
    CrossrefPubMedGoogle Scholar
  • 2 Rock GA, Palmer DS. Intermediate purity Factor VIII production utilizing a cold-insoluble globulin technique. Thromb Res 1980; 18: 551-6
    CrossrefPubMedGoogle Scholar
  • 3 Rock G, Smiley RK, Tittley P, Palmer DS. In vivo effectiveness of a high yield Factor VIII concentrate prepared in a blood bank. New Engl J Med 1984; 311: 310-3
    CrossrefPubMedGoogle Scholar
  • 4 Smit Sibinga CT, Welbergen H, Das PC. High-yield method of production of freeze-dried purified Factor VIII by blood banks. Lancet 1981; ii: 449-50
    PubMedGoogle Scholar
  • 5 Allain JP, Gazengel C, Sultan Y. et al Clinical evaluation of heat-treated high-purity factor VIII concentrate. Ric Clin Lab 1986; 16: 245
    PubMedGoogle Scholar
  • 6 Colombo M, Mannucci PM, Carnelli V. Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet 1985; ii: 1-4
    PubMedGoogle Scholar
  • 7 Preston FE, Hay CR M, Dewar MS, Greaves M, Triger DR. Non-A, non-B hepatitis and heat-treated factor VIII concentrate. Lancet 1985; ii: 231
    PubMedGoogle Scholar
  • 8 Gomperts ED. Procedures for the inactivation of viruses in clotting factor concentrates. Am J Hematol 1986; 23: 295-305
    CrossrefPubMedGoogle Scholar
  • 9 Horowitz B, Lippin A, Chang MY, Shulman RW, Vandersande J, Stryker MH, Woods KR. Preparation of antihemophilic factor and fibronectin from human plasma cryoprecipitate. Transfusion 1984; 24: 357-62
    CrossrefPubMedGoogle Scholar
  • 10 Smith JK, Evans DR, Stone V, Snape TJ. A Factor VIII concentrate of intermediate purity and higher potency. Transfusion 1979; 19: 299-306
    CrossrefPubMedGoogle Scholar
  • 11 Brcckenridge RT, Ratnoff OD. Studies on the nature of the circulating anticoagulant directed against antihemophilic factor: With notes on an assay for antihemophilic factor. Blood 1962; 20: 137-47
    PubMedGoogle Scholar
  • 12 Rock GA, Cruickshank WH, Tackaberry ES, Ganz PR, Palmer DS. Stability of VIII: C in plasma: The dependence on protease activity and calcium. Thromb Res 1983; 29: 521-35
    CrossrefPubMedGoogle Scholar
  • 1 Rock GA. FVIII: C one-stage assay of plasma containing heparin. In: Development Systems for Efficient Separation of Factor VIII from Human Fresh-frozen Plasma. Lane RS, Rock GA, Smit Sibinga CTh. (eds). Proceedings of a Workshop on Factor VIII;; Groningen, The Netherlands: 23.11.1981. pp 26-30
    Google Scholar
  • 14 Zimmerman TS, de la Pointe LI, Edgington TS. Interaction of Factor VIII antigen in hemophilic plasmas with human antibodies to Factor VIII. J Clin Invest 1977; 59: 984-9
    CrossrefPubMedGoogle Scholar
  • 15 MacFarlane DE, Stibbe J, Kirby EP, Zucker MB. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-7
    PubMedGoogle Scholar
  • 16 Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of Factor VIII/von Willebrand factor following administration of DDAVP: Implications for pathophysiology and therapy of von Willebrand’s disease subtypes. Blood 1982; 59: 1272-8
    PubMedGoogle Scholar
  • 17 Palmer DS, Harris AS, Tittley P, Rock G. The effectiveness, specificity and safety of intranasal DDAVP treatment of normal blood donors. Haemostasis 1988; 18: 187-96
    PubMedGoogle Scholar
  • 18 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75
    PubMedGoogle Scholar
  • 19 Moore BP L. Serological and Immunological Methods. 8th. ed Hunter Rose Co; Toronto, Ont: 1980. pp 73-84
    Google Scholar
  • 20 Issitt PD. Applied Blood Group Serology. 3rd. ed Montegomery Scientific Publications; Miami, FL: 1985: 27
    Google Scholar
  • 21 Scholz E. Karl Fischer Titration - Determination of Water. Springer-Verlag; New York: 1984
    Google Scholar
  • 22 Mitchell Jr J, Smith DM. Aquametry Part III: A Treatise on Methods for the Determination of Water. 2nd. ed John Wiley & Sons; New York: 1977
    Google Scholar
  • 23 Rock GA, Tackaberry ES, Palmer DS. Factors affecting the relative distribution of high and low molecular weight forms of Factor VIII. Thromb Res 1979; 14: 573-87
    CrossrefPubMedGoogle Scholar
  • 24 Rock G, Palmer DS. Accumulative effect of DDAVP and heparin in increasing plasma factor VIII levels. Vox Sang 1981; 41: 56-60
    CrossrefPubMedGoogle Scholar
  • 25 Melief CJ M, Goudsmits J. Transmission of lymphotropic retroviruses (HTLV-I and LAV/HTLV-III) by blood transfusion and blood products. Vox Sang 1986; 50: 1-11
    CrossrefPubMedGoogle Scholar
  • 26 Evatt BL, Ramsey RB, Lawrence DN. The acquired immunodeficiency syndrome in patients with hemophilia. Ann Intern Med 1984; 100: 499-504
    CrossrefPubMedGoogle Scholar
  • 27 Aronson DL, Menache D. Prevention of infectious disease transmission by blood and blood products. Prog Hematol 1978; XV: 221-41
    PubMedGoogle Scholar
  • 28 Van den Berg W, Ten Cate JW, Breederveld C, Goudsmit J. Seroconversion to HTLV-VIII in a haemophiliac given heat-treated factor VIII concentrate. Lancet 1986; i: 803-4
    PubMedGoogle Scholar
  • 29 White GC, Mathews TJ, Weinhold KJ, Haynes BF, Le Roy Cromartie H, McMillan CW, Bolgnesi DP. HTLV III seroconversion associated with heat-treated factor VIII concentrate. Lancet 1986; i: 611-2
    PubMedGoogle Scholar
  • 30 Evans DR, Robinson AE, Smith JK. Plasma fractionation and machine plasmapheresis. Plasma Ther Trans Technol 1986; 7: 33-40
    PubMedGoogle Scholar
  • 31 Hilfenhaus J, Weidmann E. Pasteurization as an efficient method to inactivate blood borne viruses in Factor VIII concentrates. Drug Res 1986; 36: 621-5
    PubMedGoogle Scholar
  • 32 Allain JP, Masson PL, Dolkart RE. The case for heat-treated products. Lancet 1985; i: 814-5
    PubMedGoogle Scholar
  • 33 Thomas KB, McGrath KM, Taylor M, Young IF, Herrington RW, Schiff P. Effect of virucidal heat-treatment on proteins in human factor VIII concentrates. Transfusion 1988; 28: 8-13
    CrossrefPubMedGoogle Scholar
  • 34 Piskiewicz D, Thomas W, Lieu MY, Tse D, Sarno L. Virus inactivation by heat treatment. In: Morgenthaler JJ. (ed). Virus Inactivation in Plasma Products. Curr Stud Hematol Blood Transfus; Basel, Karger: 1989. No 56 pp 44-54
    Google Scholar
  • 35 Winkleman L, Feldman PA, Evans DR. Severe heat-treatment of lyophilized coagulation factors. In: Morgenthaler JJ. (ed) Virus Inactivation in Plasma Products. Curr Stud Hematol Blood Transfus; Basel, Karger: 1989. No 56 pp 55-9
    Google Scholar
  • 36 Bloom AL. Hemophilia and AIDS. Lancet 1985; i: 336
    PubMedGoogle Scholar
  • 37 Edwards CA, Piet MP J, Chin S, Horowitz B. Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang 1987; 52: 53-9
    CrossrefPubMedGoogle Scholar
  • 38 Prince AM, Horowitz B, Brotman B, Huima T, Richardson L, van den Ende MC. Inactivation of hepatitis B and Hutchison strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang 1984; 46: 36-43
    CrossrefPubMedGoogle Scholar
  • 39 Prince AM, Horowitz B, Brotman B. Sterilization of hepatitis and HTLV-III viruses by exposure to tri(n-butyl) phosphate and sodium cholate. Lancet 1986; i: 706-10
    PubMedGoogle Scholar
  • 40 Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of virus in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl) phosphate detergent conditions. Transfusion 1985; 25: 516-22
    CrossrefPubMedGoogle Scholar
  • 41 Berntorp E, Nilsson IM. Use of a high purity Factor VIII concentrate (Haemate P) in von Willebrand’s Disease. Vox Sang 1989; 56: 212-7
    PubMedGoogle Scholar
  • 42 Fukui H, Nishino M, Terada S, Nishikuba T, Yoshioka A, Kinoshita S, Niimoni K, Yoshioka K. Hemostatic effect of a heat-treated Factor VIII concentrate (Haemate P) in von Willebrand’s Disease. Blut 1988; 56: 171-8
    CrossrefPubMedGoogle Scholar
  • 43 Blatt PM, Brinkhous KM, Culp HR, Krauss JS, Robert HR. Antihemophilic factor concentrate therapy in von Willebrand’s Disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. JAMA 1976; 236: 2770-2
    CrossrefPubMedGoogle Scholar
  • 44 Green D, Potter EV. Failure of AHF concentrates to control bleeding in von Willebrand’s Disease. Am J Med 1976; 60: 357-60
    CrossrefPubMedGoogle Scholar
  • 45 Mazurier C, de Romeuf C, Parquet-Gernez A, Jorieux S, Goudeman M. In vitro and in vivo evaluation of Factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Vox Sang 1987; 52: 265-71
    CrossrefPubMedGoogle Scholar
  • 46 Cash JD. Blood replacement therapy. In: Bloom AL, Thomas DP. (eds) Haemostasis and Thrombosis. 2nd. ed Churchill Livingston; London: 1987: 596
    Google Scholar
  • 47 Newman J, Johnson AJ, Karpatkin MH, Puszkin S. Methods for the preparation of clinically effective intermediate and high-purity Factor-VIII concentrate. Br J Haematol 1971; 21: 1-20
    CrossrefPubMedGoogle Scholar